On December 4, 2020, the Biotechnology Innovation Organization (BIO), the California Life Sciences Association (CLSA), and BIOCOM California today filed a challenge against the Department of Health and Human Services’ (HHS) attempt, during the final days of the Trump Administration, to implement for the first time ever a “Most Favored Nation” reimbursement policy for certain drugs administered by Medicare Part B providers – drastically altering this system in ways that will harm their ability to serve America’s most vulnerable senior citizens.Continue reading
Author Archive: AZBio
Governor Ducey Announces Latest Actions To Fight COVID-19, Increase Hospital Staffing
Governor Ducey Announces Latest Actions To Fight COVID-19, Increase Hospital StaffingContinue reading
Applications open for fall 2021 cohort of new learning-by-doing master’s degree in innovation
Have you dreamed of starting your own business? Are you obsessed with the idea of making the world a better place? Are you impatient for progress? Do you have a great idea, but don’t know where to start?Continue reading
AquaVitas, LLC Announces Contract from U.S. Government and Health and Human Services for Nationwide Testing of Wastewater for SARS-CoV-2
Award will fund a collaborative effort between AquaVitas, LLC, the Centers for Disease Control and Prevention and Health and Human Services to identify best practices for wastewater SARS- CoV-2 assessment and subsequent data analytics across the U.S.
Phase 1 award will fund assessment of wastewater at up to 100 treatment plants (representing ~10% of the U.S. population).
Optional Phase 2 award will scale to fund assessment of wastewater at up to 340 treatment plants (representing ~30% of the U.S. population in at least 42 states).Continue reading
Calviri Appoints Michael McCallister to Board of Directors
TEMPE, Ariz.–(BUSINESS WIRE)–Calviri, Inc. (www.calviri.com) announces today the appointment of Michael McCallister to the company’s Board of Directors. Mr. McCallister has a breadth of governance and management experience in multiple industries, including health insurance, financial services, and animal life sciences.Continue reading
GT Medical Technologies Announces $16 Million Financing to Expand Availability of Targeted Therapy for Patients with Recurrent Brain Tumors
GammaTile Therapy Offers Patients a Proven Option to Slow Brain Tumor Progression, Delay Recurrence and Avoid Additional Trips to the Hospital for Radiation TherapyContinue reading
Regeneron’s REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization
First treatment of any kind to have prospectively confirmed and statistically significant anti-viral activity against SARS-CoV-2
Authorized for recently diagnosed, mild to moderate COVID-19 in high-risk patients
Initial doses of REGEN-COV2 will be made available to approximately 300,000 patients, with no medication out-of-pocket costs, under U.S. government allocation programContinue reading
Banner Health recommends alternatives to in-person gatherings this Thanksgiving
PHOENIX (November 17, 2020) – The United States is experiencing uncontrollable spread of COVID-19, and social gatherings are an important contributor to the rise in COVID-19 cases. Banner Health advises that individuals evaluate the risk level of their Thanksgiving plans and consider safer alternatives for those activities that present a higher risk of contracting or spreading the virus.Continue reading